{"groups":[{"description":"All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.\n\nfludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \\<40%, DLCO\\<50%, LVEF\\<40, Serum bilirubin \\>1.5 mg% or serum transaminases \\> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.","id":"FG000","title":"Fludarabine/Busulfan + ATG"},{"description":"All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.\n\nfludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \\<40%, DLCO\\<50%, LVEF\\<40, Serum bilirubin \\>1.5 mg% or serum transaminases \\> 2x nl).","id":"FG001","title":"Fludarabine/Melphalan + ATG"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Criteria for FluBu conditioning: \\<60 years old; no diagnosis of myeloma or myelofibrosis (MF) in chronic phase; and not having received an autologous stem cell transplant with the last 2 years. Patients not fulfilling these criteria but still eligible for allogeneic transplantation were prepared with FluMel.","recruitmentDetails":"We analyzed the clinical outcome of patients with hematological malignancies at standard or high-risk, who were transplanted (allogeneic peripheral blood or BMT HSCT) after receiving FluBU as a conditioning regimen. A total of 30 patients were recruited for this study which was conducted at the UIC Medical Center Inpatient BMT unit."}